FindTrial
Sign In

Cycloserine

DRUG14 trials

Sponsors

Universiteit Maastricht, Yale University, National Institute of Allergy and Infectious Diseases (NIAID), University of Arkansas, Baylor College of Medicine

Conditions

Drug DependenceHIV InfectionsMajor Depressive DisorderMajor Depressive Disorder (MDD)Motor ActivityMultidrug Resistant TuberculosisNicotine AddictionOpioid-Related Disorders

Phase 1

Drug Discrimination in Methadone-Maintained Humans Study 1
CompletedNCT00593463
University of ArkansasDrug Dependence
Start: 2006-09-30End: 2010-05-31Target: 40Updated: 2011-03-11
Investigation of Cycloserine as a Smoking Cessation Treatment
CompletedNCT01062932
Baylor College of MedicineNicotine Addiction
Start: 2009-05-31End: 2010-09-30Updated: 2012-07-27
Cycloserine in the Treatment of Sleep Apnea
TerminatedNCT02735694
University of ManitobaSleep Apnea Syndromes
Start: 2015-09-30End: 2016-11-30Updated: 2019-09-17
Cycloserine rTMS Plasticity Augmentation
CompletedNCT03432689
University of CalgaryMotor Activity
Start: 2018-08-06End: 2018-11-07Updated: 2018-11-09
Cycloserine rTMS Plasticity Augmentation in Depression
CompletedNCT03511599
University of CalgaryMajor Depressive Disorder
Start: 2018-09-03End: 2021-04-21Updated: 2022-01-05

Phase 2

Neurobiology of Opioid Dependence: 3 - 3
WithdrawnNCT00000194
Yale UniversityOpioid-Related Disorders
Start: 1993-01-31End: 1998-01-31Updated: 2016-05-06
Repeated iTBS Cycloserine Motor Plasticity
CompletedNCT05081986
University of CalgaryMotor Activity
Start: 2021-08-18End: 2022-02-23Updated: 2023-09-07
TMSxDCS: Pharmacologically augmenting transcranial magnetic stimulation for depression
Not yet recruitingCTIS2025-521166-95-00
Universiteit MaastrichtMajor Depressive Disorder (MDD)
Target: 48Updated: 2025-06-02

Phase 3

Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort
Active, not recruitingNCT06081361
Beijing Chest HospitalPulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
Start: 2023-12-22End: 2026-12-31Target: 186Updated: 2025-04-01

Phase 4

A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China
NCT05306223
Beijing Chest HospitalTuberculosis, Multidrug-Resistant
Start: 2022-05-10End: 2025-08-08Target: 212Updated: 2023-01-18

Unknown Phase

A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.
CompletedNCT00000796
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections, Tuberculosis
End: 1998-10-31Target: 525Updated: 2021-11-03
The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers
CompletedNCT00633256
Yale UniversitySmoking
Start: 2006-12-31End: 2008-02-29Updated: 2012-04-11
Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS
CompletedNCT04717908
Huashan HospitalMultidrug Resistant Tuberculosis
Start: 2021-01-20End: 2024-06-22Updated: 2024-11-12
6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province
Not yet recruitingNCT07198685
Wuhan Pulmonary HospitalTreatment Duration, Treat to Target
Start: 2025-09-30End: 2028-09-30Target: 52Updated: 2025-09-30

Related Papers

Evaluation of an oral bedaquiline regimen for treating multidrug-resistant TB in China: a randomized trial.
2026-04-02
Acquired Resistance in Different Treatment Cohorts for Rifampicin-resistant Tuberculosis: Results from the TB-TRUST and TB-TRUST-plus Trials
American Journal of Respiratory and Critical Care Medicine2025-05-01
A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT.
2024-04-011 citations
Rapid Detection of Extensive Drug Resistance by Xpert MTB/XDR Optimizes Therapeutic Decision-Making in Rifampin-Resistant Tuberculosis Patients.
2023-05-3011 citations